Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | BRD1 | O95696 | 2/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.36 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21112298 | 1.00 | MEN1 (0.39) | MEN1KMT2AALOX5SMN1; SMN2BRD4 | |
| SCHEMBL29640227 | 0.89 | MMP1 (0.36) | MEN1KMT2AALOX5SMN1; SMN2BRD4 | |
| SCHEMBL20908216 | 0.89 | MMP1 (0.36) | MEN1KMT2AALOX5SMN1; SMN2BRD4 | |
| SCHEMBL20907575 | 0.82 | MMP1 (0.34) | MEN1KMT2AALOX5SMN1; SMN2BRD4 | |
| SCHEMBL21148935 | 0.82 | MMP1 (0.34) | MEN1KMT2AALOX5SMN1; SMN2BRD4 | |
| SCHEMBL21112715 | 0.81 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2CTSSMGLL | |
| SCHEMBL21112713 | 0.81 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2CTSSMGLL | |
| SCHEMBL21112347 | 0.80 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2CTSSMGLL | |
| SCHEMBL21112351 | 0.80 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2CTSSMGLL | |
| SCHEMBL21112128 | 0.79 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2CTSSMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | MEN1 2814/4885KMT2A 1556/4885ALOX5 3256/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | MEN1 2814/4885KMT2A 1556/4885ALOX5 3256/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | MEN1 2814/4885KMT2A 1556/4885ALOX5 3256/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | MEN1 463/4885KMT2A 1129/4885ALOX5 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.